5 Results for "

RET oncoproteins

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "RET oncoproteins" in MCE Product Catalog:

  • Targets Recommended:
Cat. No.: HY-34595
CAS No.: 2380-63-4
Target:  

RET

Research Areas:  

Cancer

Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity .
loading...
    loading...
Cat. No.: HY-34595R
CAS No.: 2380-63-4
Target:  

RET

Research Areas:  

Cancer

Pyrazoloadenine (Standard) is the analytical standard of Pyrazoloadenine. This product is intended for research and analytical applications. Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity .
loading...
    loading...
Cat. No.: HY-180550
Target:  

PROTACs RET Trk Receptor

Research Areas:  

Endocrinology Cancer

ZW-18-116 (compound 9) is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-18-116 induces the degradation of oncoproteins TRKA and RET by recruiting the CRBN E3 ligase. ZW-18-116 exhibits potent anti-proliferative activity in various cancer cell lines harboring RET or TRKA fusions. ZW-18-116 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers .
loading...
    loading...
Cat. No.: HY-180551
Target:  

PROTACs RET Trk Receptor

Research Areas:  

Endocrinology Cancer

ZW-6-052 (compound 20), the derivative of ZW-18-116 (HY-180550), is a dual-target PROTAC degrader for the oncoproteins TRKA and RET. ZW-6-052 induces degradation of TMP3-TRKA in KM12 mouse xenograft models. ZW-6-052 can be used for RET or TRKA-derived cancer research, such as thyroid, lung, and colon cancers .
loading...
    loading...
Cat. No.: HY-183931
CAS No.: 1839155-15-5
Target:  

RET VEGFR Trk Receptor c-Fms

Research Areas:  

Cancer

NPA101.3 is an orally active RET receptor tyrosine kinase and VEGFR2 inhibitor (RET IC50 = 0.001 μM, RET V804M IC50 = 0.008 μM, VEGFR2 IC50 = 0.003 μM). NPA101.3 inhibits purified TRKA (IC50 = 32 nM) and CSF1R (IC50 = 46 nM). NPA101.3 completely suppresses tumor formation in RET /C634Y-transformed cells and also attenuates tumor formation in HRAS /G12V-transformed cells. NPA101.3 can be used in the research of RET-driven cancers .
loading...
    loading...